Tivic Health Shares Jump 31% as ncVNS Trial and ClearUP Success Spark Optimism

Introduction to Tivic Health Systems Inc

Tivic Health Systems Inc (NASDAQ: TIVC) is a bioelectronic medicine and immunotherapeutics company founded in 2016. As of August 20, 2025, the stock closed at $4.0098, reflecting a 31.47% increase on a trading volume of 2,878,237 shares on the NASDAQ exchange.

Metric	Value
Share Price	$4.0098
Change (%)	+31.47%
Volume	2,878,237
Exchange	NASDAQ (TIVC)

Corporate Structure and Leadership

Tivic Health employs between 11 and 50 professionals across research, engineering, regulatory affairs, and corporate functions. Jennifer Ernst serves as Chief Executive Officer, overseeing strategic direction and capital markets activities. Blake Gurfein, Ph.D., serves as Chief Scientific Officer, leading bioelectronic research, while Dr. Chandra Sekhar Durisety focuses on product development and commercialization.

Bioelectronic Medicine by National Cancer Institute

Product Portfolio and Clinical Developments

Tivic’s flagship consumer product, ClearUP®, is an FDA-cleared, drug-free device designed for sinus pain relief. In clinical trials, 88% of users reported a reduction in congestion, and 97% found the device user-friendly. Over 50,000 units have been distributed through a 90-day risk-free trial program.

On July 22, 2025, Tivic announced the completion of a non-invasive vagus nerve stimulation (ncVNS) study conducted in collaboration with The Feinstein Institute for Bioelectronic Medicine. The study indicated reproducible modulation of the autonomic nervous system in healthy subjects, suggesting potential applications in conditions such as epilepsy, post-traumatic stress disorder, and ischemic stroke rehabilitation.

Financial and Strategic Overview

In its Form 10-Q filed on August 14, 2025, Tivic reported trailing twelve-month revenue of $462,000 and a net loss of $6.34 million (EPS: –$5.05). As of June 30, 2025, the balance sheet showed cash reserves of $1.18 million and no long-term debt. Key financial metrics include a market capitalization of $3.94 million, a price/sales ratio of 3.05, and a price/book ratio of 1.30.

Strategically, Tivic is advancing two core platforms:

• Bioelectronic Sinus Relief: Continued marketing and incremental feature enhancements for ClearUP.
• Immunotherapeutics & ncVNS: Development of TLR5 biologics and next-generation non-invasive devices targeting chronic inflammatory and neurological conditions.

Partnerships with academic and clinical institutions support regulatory submissions and product optimization.

Market Position within Bioelectronic Medicine

The global neurostimulation market was valued at $8.3 billion in 2023, with a projected growth rate of 12.2% CAGR through 2032. Tivic’s non-invasive approach distinguishes it from implantable VNS systems by offering symptom relief without drugs and minimal side effects. In the consumer health segment, ClearUP competes with over-the-counter remedies by providing precision-targeted microcurrent therapy. In prescription markets, the ncVNS pipeline positions Tivic against both surgical implant manufacturers and emerging non-invasive device makers.

tl;dr

• On August 20, 2025, TIVC shares rose 31.47% to $4.0098 on NASDAQ.
• Form 8-K filed August 20, 2025, and Form 10-Q filed August 14, 2025 reflect $462,000 in trailing revenue, $6.34 million net loss, and $1.18 million in cash.
• July 22, 2025 study with The Feinstein Institute validated ncVNS effects, indicating potential clinical applications in epilepsy, PTSD, and stroke rehabilitation.
• ClearUP trials indicate 88% congestion relief and 97% user satisfaction among over 50,000 customers.
• Pipeline includes TLR5 biologics and next-generation ncVNS devices, with regulatory submissions and product launches anticipated through 2026.